EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Therapeutic Enoxaparin Dosing in Obesity

Marcelle Appay iD, Shreyas Kharadi, Sajani Nanayakkara, Ji Sang Ryu, Leonardo Pasalic, Jan-Willem Alffenaar

Annals of Pharmacotherapy · 2025-03 · 59 (3) · 262-276

DOI: 10.1177/10600280241256351 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 19.06.2024. Verfasst von Marcelle Appay und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Enoxaparin, Obesity, Anticoagulants. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: australian government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This review aims to systematically summarize the available data on efficacy and safety of therapeutic enoxaparin in obese patients and to identify gaps to guide future research. Data Sources: Medline and Embase were systematically searched for eligible studies (last searched December 20, 2023). Studies were included if they reported on therapeutic dosing regimens, adverse bleeding, thrombotic outcomes, or antifactor Xa (AFXa) monitoring in obese adult patients. Study Selection and Data Extraction: The systematic review management tool Covidence was used to manage the study selection and data extraction process. The reference list from eligible studies was screened to determine any additional eligible studies. Data Synthesis: Sixteen studies were included in the analysis. Studies used a variety of doses, indications, and study designs making comparison difficult. Twelve studies reported the incidence of thrombotic events (median = 1.3% [interquartile range [IQR] = 0.3%-2.3%]) and all studies reported the incidence of bleeding events (median = 5.7% [IQR = 2.4%-14.5%]). Two of the 8 studies analyzing the influence of weight/body mass index (BMI) or dose per kg on AFXa levels reported statistically significant results. One study concluded that BMI did not affect achievement of target AFXa levels. However, the second study found that dosing using actual body weight was an independent predictor of supratherapeutic AFXa levels in the obese population. Relevance to Patient Care and Clinical Practice: This is the first comprehensive review with a focus on therapeutic dosing of enoxaparin in obesity and has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Seven of the included studies were published since 2018 indicating that new evidence on this topic is emerging.

Conclusion

There was inadequate evidence to support an optimal dosing strategy in obese patients due to the heterogeneity of the studies. The AFXa monitoring may be appropriate to guide dosing in this population. Further research is required to determine a suitable dosing regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinObesityAnticoagulantsHumansHemorrhageDose-Response Relationship, DrugBody Mass IndexThrombosis

Stichwörter der Autor:innen

AFXa levelsAntifactor Xa levelsLMWHenoxaparinlow molecular weight heparinobesitytreatment

Substanzen

EnoxaparinAnticoagulants

Autor:innen und Institutionen

  • School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Department of Pharmacy, John Hunter Hospital, Newcastle, NSW, Australia.
  • School of Medicine, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Sydney, NSW, Australia.
  • Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
  • Department of Pharmacy, Westmead Hospital, Sydney, NSW, Australia.

ORCID-Profile: Marcelle Appay

Förderung

  • australian government

Zitieren

APA

Appay, M., Kharadi, S., Nanayakkara, S., Ryu, J. S., Pasalic, L., & Alffenaar, J. W. (2025). Therapeutic Enoxaparin Dosing in Obesity. Annals of Pharmacotherapy, 59(3), 262-276. https://doi.org/10.1177/10600280241256351

Vancouver

Appay M, Kharadi S, Nanayakkara S, Ryu JS, Pasalic L, Alffenaar JW. Therapeutic Enoxaparin Dosing in Obesity. Annals of Pharmacotherapy. 2025;59(3):262-276. doi:10.1177/10600280241256351

BibTeX
@article{Appay2025,
  author = {Appay, Marcelle and Kharadi, Shreyas and Nanayakkara, Sajani and Ryu, Ji Sang and Pasalic, Leonardo and Alffenaar, Jan-Willem},
  title = {Therapeutic Enoxaparin Dosing in Obesity},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  volume = {59},
  number = {3},
  pages = {262--276},
  doi = {10.1177/10600280241256351}
}
Kostenlos starten →